Sign In
Buy SXTP
$1.68
-0.0100 (-0.592%)
At Close: Jun 23, 2026
License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter
Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Minimum enrollment to support interim analysis expected as soon as early July 2026 Randomized, double-
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
08:42am, Friday, 15'th May 2026
WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectiou
60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) Sees Significant Decline in Short Interest
04:10am, Saturday, 11'th Apr 2026
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP - Get Free Report) was the target of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalin
60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know
01:01pm, Friday, 03'rd Apr 2026
60 Degrees Pharmaceuticals Inc. (SXTP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
60 Degrees Pharmaceuticals Announces 2025 Annual Results
07:01am, Tuesday, 31'st Mar 2026
FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Ph
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
08:01am, Wednesday, 18'th Mar 2026
60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strategy.
What's Going On With 60 Degrees Pharmaceuticals On Friday?
09:11am, Friday, 13'th Mar 2026
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are down during Friday's premarket session. This follows a 9.6% decline, closing at $2.91 on Thursday.
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
07:24am, Wednesday, 11'th Mar 2026
All three patients in 60 Degrees Pharma's expanded access study were cured of relapsing babesiosis after tafenoquine treatment, supporting guideline review
Analyzing Rafael (NYSE:RFL) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)
03:03am, Friday, 20'th Feb 2026
Rafael (NYSE: RFL - Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ: SXTP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two bus
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
08:01am, Monday, 02'nd Feb 2026
GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine) Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company's marketing strategy Partners
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Shares to Reverse Split on Tuesday, January 20th
01:19am, Friday, 16'th Jan 2026
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are set to reverse split on the morning of Tuesday, January 20th. The 1-4 reverse split was recently announced. The number of shares owned by shar
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
08:01am, Thursday, 15'th Jan 2026
WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new me
Peer-reviewed NC State study found Babesia in 24% of chronic fatigue patients, supporting further study of chronic babesiosis and ARAKODA® evaluation.
Here's Why 60 Degrees Pharmaceuticals Inc. (SXTP) Looks Ripe for Bottom Fishing
10:56am, Tuesday, 23'rd Dec 2025
60 Degrees Pharmaceuticals Inc. (SXTP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate re
